Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Infect Drug Resist ; 17: 3677-3688, 2024.
Article in English | MEDLINE | ID: mdl-39205797

ABSTRACT

Purpose: Human papillomavirus (HPV) infection is a prevalent sexually transmitted infection worldwide, with its persistence being a significant factor in the development of cervical cancer and precancerous lesions. Understanding the prevalence and genotypes distribution of HPV can aid in the implementation of more focused strategies for cervical cancer prevention and treatment. This study aimed to investigate the prevalence and genotype distribution of HPV infection among outpatient-based populations in Wuhan, China. Methods: Our study retrospectively analyzed the results of cervical HPV screening in 14,492 outpatient women. The cervicovaginal infection of 18 high-risk genotypes and 10 low-risk genotypes were analyzed by PCR and reverse dot hybridization techniques. Results: The overall prevalence of HPV infection in the outpatient female population was 15.33%, with a predominance of single infection and a predominance of dual infection among multiple infections. The top five genotypes in terms of prevalence of HR-HPV and LR-HPV were HPV-52 (3.77%), 53 (1.46%), 16 (1.31%), 58 (1.19%), 39 (1.18%) for HR-HPV, and HPV-54 (1.23%), 61 (1.08%), 81 (1.04%), 42 (0.87%), 44 (0.70%) for LR-HPV. Two peaks of HPV infection prevalence were observed among women under 25 years (22.88%) and over 56 years (24.26%). The prevalence and genotype distribution of HPV infection varied among different outpatient populations, with higher rates of HPV single infection, multiple infections, and infection across all ages observed in the gynecology outpatient population compared to the health check-up population. Conclusion: This study revealed the HPV prevalence and genotype distribution among different outpatient populations in Wuhan city, which may provide guidance for HPV vaccination and cervical cancer prevention strategies in the region.

2.
Medicine (Baltimore) ; 103(17): e38053, 2024 Apr 26.
Article in English | MEDLINE | ID: mdl-38669357

ABSTRACT

To explore the anticoagulant effect and safety of utilizing different doses of rivaroxaban for the treatment of patients with atrial fibrillation (AF) in the real world. A retrospective case-control analysis was performed by applying the hospital database, and 3595 patients with non-valvular atrial fibrillation (NVAF) who were hospitalized and taking rivaroxaban at Wuhan Asia Heart Hospital and Wuhan Asia General Hospital from March 2018 to December 2021 were included in the study, and were divided into the rivaroxaban 10 mg and 15 mg groups according to the daily prescribed dose, of which 443 cases were in the 10 mg group and 3152 cases were in the 15 mg group. The patients were followed up regularly, and the incidence of thrombotic events, bleeding events and all-cause deaths were recorded and compared between the 2 groups, and logistic regression was applied to analyze the influencing factors for the occurrence of adverse events. Comparison of the incidence of thrombosis, bleeding and all-cause death between the 2 groups of patients showed that the 10 mg group was higher than the 15 mg group, but the difference was not statistically significant (χ2 = 0.36, 3.26, 1.99, all P > .05); the incidence of total adverse events between the 2 groups of patients was higher in the 10 mg group than in the 15 mg group, with a statistically significant difference (χ2 = 4.53, P = .033); multifactorial logistic regression results showed that age [OR (95% CI) = 1.02 (1.00-1.04)], diabetes mellitus [OR (95% CI) = 1.69 (1.09-2.62)], D-dimer level [OR (95% CI) = 1.06 (1.00-1.11)] and persistent AF [OR (95% CI) = 1.54 (1.03-2.31)] were risk factors for adverse events (P < .05). In the real world, Asian clinicians recommend rivaroxaban 10 mg once daily for NVAF patients for a variety of reasons; however, this dose is not superior or even inferior to the 15 mg group in terms of effectiveness and safety. Advanced age, elevated D-dimer levels, history of diabetes mellitus, and persistent AF are risk factors for adverse events, and the optimal dosage of rivaroxaban or optimal anticoagulation strategy for Asian patients with nonvalvular AF requires further study.


Subject(s)
Atrial Fibrillation , Dose-Response Relationship, Drug , Factor Xa Inhibitors , Hemorrhage , Rivaroxaban , Humans , Rivaroxaban/administration & dosage , Rivaroxaban/adverse effects , Rivaroxaban/therapeutic use , Atrial Fibrillation/drug therapy , Atrial Fibrillation/complications , Male , Female , Retrospective Studies , Aged , Factor Xa Inhibitors/administration & dosage , Factor Xa Inhibitors/therapeutic use , Factor Xa Inhibitors/adverse effects , Middle Aged , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Case-Control Studies , Incidence , Thrombosis/epidemiology , Thrombosis/prevention & control , Thrombosis/etiology , Risk Factors , Aged, 80 and over
3.
Chin J Integr Med ; 28(12): 1137-1146, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36169875

ABSTRACT

Chinese medicine (CM) has thousands of years of experience in prevention of diseases. As for CM, people's constitution is closely related to their health status, thus recognition of CM constitution is the fundamental and core content of research on constitution types. With development of technologies such as sensors, artificial intelligence and big data, objectification of the four diagnostic methods of CM has gradually matured, bringing changes in the mindset and innovations in technical means for recognition of CM constitution. This paper presents a systematic review of the latest research trends in constitution recognition based on objectification of diagnostic methods in CM.


Subject(s)
Artificial Intelligence , Medicine, Chinese Traditional , Humans , Health Status , Body Constitution
5.
Rev Sci Instrum ; 91(4): 043503, 2020 Apr 01.
Article in English | MEDLINE | ID: mdl-32357700

ABSTRACT

The electron cyclotron heating system including four gyrotrons is being developed in the Institute of Plasma Physics, Chinese Academy of Sciences. The filament is an important part of the gyrotron, which is used to heat the cathode. The gyrotron output power can be controlled by adjusting the filament power. We have developed the filament power control and measurement system using Labview. The filament characteristics were tested using this power control system. The test results show that the filament current can be fitted with the e-exponential function of the filament voltage. It can be seen that as the voltage increases, the filament resistance gradually increases. We have developed a new "burst" function to prevent the beam current from dropping too fast, which is conducive to long pulse stable operation of the gyrotrons.

6.
J Thromb Haemost ; 18(6): 1324-1329, 2020 06.
Article in English | MEDLINE | ID: mdl-32306492

ABSTRACT

BACKGROUND: The outbreak of the coronavirus disease 2019 (Covid-19) has shown a global spreading trend. Early and effective predictors of clinical outcomes are urgently needed to improve management of Covid-19 patients. OBJECTIVE: The aim of the present study was to evaluate whether elevated D-dimer levels could predict mortality in patients with Covid-19. METHODS: Patients with laboratory confirmed Covid-19 were retrospective enrolled in Wuhan Asia General Hospital from January 12, 2020, to March 15, 2020. D-dimer levels on admission and death events were collected to calculate the optimum cutoff using receiver operating characteristic curves. According to the cutoff, the subjects were divided into two groups. Then the in-hospital mortality between two groups were compared to assess the predictive value of D-dimer level. RESULTS: A total of 343 eligible patients were enrolled in the study. The optimum cutoff value of D-dimer to predict in-hospital mortality was 2.0 µg/mL with a sensitivity of 92.3% and a specificity of 83.3%. There were 67 patients with D-dimer ≥2.0 µg/mL, and 267 patients with D-dimer <2.0 µg/mL on admission. 13 deaths occurred during hospitalization. Patients with D-dimer levels ≥2.0 µg/mL had a higher incidence of mortality when comparing with those who with D-dimer levels <2.0 µg/mL (12/67 vs 1/267, P < .001; hazard ratio, 51.5; 95% confidence interval, 12.9-206.7). CONCLUSIONS: D-dimer on admission greater than 2.0 µg/mL (fourfold increase) could effectively predict in-hospital mortality in patients with Covid-19, which indicated D-dimer could be an early and helpful marker to improve management of Covid-19 patients. (Chinese Clinical Trial Registry: ChiCTR2000031428).


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/blood , Coronavirus Infections/mortality , Fibrin Fibrinogen Degradation Products/analysis , Hospital Mortality , Patient Admission , Pneumonia, Viral/blood , Pneumonia, Viral/mortality , Aged , Biomarkers/blood , COVID-19 , China , Coronavirus Infections/diagnosis , Coronavirus Infections/virology , Early Diagnosis , Female , Humans , Male , Middle Aged , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/virology , Predictive Value of Tests , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , SARS-CoV-2 , Time Factors
7.
Ther Drug Monit ; 41(6): 748-754, 2019 12.
Article in English | MEDLINE | ID: mdl-31259883

ABSTRACT

BACKGROUND: Genotype-guided warfarin dosing has been shown in some randomized trials to improve anticoagulation outcomes in individuals of European ancestry; yet, its utility in Chinese patients with heart valve replacement remains unresolved. METHODS: A total of 2264 patients who underwent heart valve replacement at Wuhan Asia Heart Hospital were enrolled in this study. Patients were randomly divided into 2 groups, namely, a genotype-guided and a traditional clinically guided warfarin dosing group. In the genotype-guided group (n = 1134), genotyping for CYP2C9 and VKORC1 (-1639 G→A) was performed using TaqMan genotyping assay. Warfarin doses were predicted with the International Warfarin Pharmacogenetics Consortium algorithm. Patients in the control group (n = 1130) were clinically guided. The primary outcome was to compare the incidence of adverse events (major bleeding and thrombotic) during a 90-day follow-up period between 2 groups. Secondary objectives were to describe effects of the pharmacogenetic intervention on the first therapeutic-target-achieving time, the stable maintenance dose, and the hospitalization days. RESULTS: A total of 2245 patients were included in the analysis. Forty-nine events occurred during follow-up. Genotype-guided dosing strategy did not result in a reduction in major bleeding (0.26% versus 0.63%; hazard ratio, 0.44; 95% confidence interval, 0.13-1.53; P = 0.20) and thrombotic events (0.89% versus 1.61%; hazard ratio, 0.56; 95% confidence interval, 0.27-1.17; P = 0.12) compared with clinical dosing group. Compared with traditional dosing, patients in the genotype-guided group reached their therapeutic international normalized ratio in a shorter time (3.8 ± 2.0 versus 4.4 ± 2.0 days, P < 0.001). There was no difference in hospitalization days (P = 0.28). CONCLUSIONS: Warfarin pharmacogenetic testing according to the International Warfarin Pharmacogenetics Consortium algorithm cannot improve anticoagulation outcomes in Chinese patients with heart valve replacement.


Subject(s)
Anticoagulants/pharmacokinetics , Anticoagulants/therapeutic use , Pharmacogenomic Testing , Warfarin/pharmacokinetics , Warfarin/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/blood , Asian People , Cytochrome P-450 CYP2C9/genetics , Dose-Response Relationship, Drug , Genotype , Heart Valve Prosthesis , Humans , International Normalized Ratio , Vitamin K Epoxide Reductases/genetics , Warfarin/administration & dosage , Warfarin/blood
8.
Nanomaterials (Basel) ; 9(7)2019 Jul 10.
Article in English | MEDLINE | ID: mdl-31295969

ABSTRACT

The spherical-graphite/Fe3O4 composite has been successfully fabricated by a simple two-step synthesis strategy. The oxygenous functional groups between spherical-graphite and Fe3O4 benefit the loading of hollow Fe3O4 nanospheres. All of the composites as anodes for half cells show higher lithium storage capacities and better rate performances in comparison with spherical-graphite. The composite containing 39 wt% of hollow Fe3O4 nanospheres exhibits a high reversible capacity of 806 mAh g-1 up to 200 cycles at 0.5 A g-1. When cycled at a higher current density of 2 A g-1, a high charge capacity of 510 mAh g-1 can be sustained, even after 1000 long cycles. Meanwhile, its electrochemical performance for full cells was investigated. When matching with LiCoO2 cathode, its specific capacity can remain at 137 mAh g-1 after 100 cycles. The outstanding lithium storage performance of the spherical-graphite/Fe3O4 composite may depend on the surface modification of high capacity hollow Fe3O4 nanospheres. This work indicates that the spherical-graphite/Fe3O4 composite is one kind of prospective anode material in future energy storage fields.

9.
Int Heart J ; 60(1): 19-26, 2019 Jan 25.
Article in English | MEDLINE | ID: mdl-30464124

ABSTRACT

Soluble suppression of tumorigenicity 2 (sST2), a biomarker representing myocardial fibrosis and inflammation, has been applied in risk stratification of patients with myocardial infarction (MI). However, whether primary PCI (PPCI) will eliminate the predictive value of sST2 in STEMI patients has not been well studied. Here, we conducted a prospective clinical trial to evaluate the correlation between sST2 and prognosis in STEMI patients undergoing PPCI. sST2 levels were measured in 295 STEMI patients (60.2 ± 10.8 years) at admission using a high sensitivity assay. Baseline sST2 levels were significantly associated with heart function, biomarkers of inflammation, and myocardial injury. During a 12-month follow-up, 19 patients had major adverse cardiovascular events (MACEs). Greater sST2 was continuously associated with a higher risk of incident MACEs. Such association remained even after adjusting for other risk factors in a multivariate Cox analysis. A baseline sST2 level in the highest quartile (≥ 58.7 ng/mL) was independently associated with mortality (HR: 5.01, 95%CI: 1.02-16.30, P = 0.048). More incident heart failure was seen in the group with greater sST2, however, the association was not significant after adjustment. Therefore, baseline sST2 may be useful to predict MACEs, especially mortality, in STEMI patients receiving PPCI.


Subject(s)
Interleukin-1 Receptor-Like 1 Protein/metabolism , Myocardial Infarction/complications , Percutaneous Coronary Intervention/instrumentation , ST Elevation Myocardial Infarction/blood , Aged , Biomarkers/blood , Female , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/surgery , Natriuretic Peptide, Brain/metabolism , Predictive Value of Tests , Prognosis , Prospective Studies , Risk Assessment , Risk Factors , ST Elevation Myocardial Infarction/complications , ST Elevation Myocardial Infarction/mortality , ST Elevation Myocardial Infarction/surgery
SELECTION OF CITATIONS
SEARCH DETAIL